Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource

Kitsada Wudhikarn; Brian J Smith; Anna M Button; Thomas M Habermann; Carrie A Thompson; Lori J Rosenstein; Sergei I Syrbu; George J Weiner; James R Cerhan; Brian K Link

doi:10.3109/10428194.2014.994206

Back

Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource

Journal article

Open access

Peer reviewed

Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource

Kitsada Wudhikarn, Brian J Smith, Anna M Button, Thomas M Habermann, Carrie A Thompson, Lori J Rosenstein, Sergei I Syrbu, George J Weiner, James R Cerhan and Brian K Link

Leukemia & lymphoma, Vol.56(8), pp.2365-2372

08/03/2015

DOI: 10.3109/10428194.2014.994206

PMID: 25530345

Files and links (1)

url

http://doi.org/10.3109/10428194.2014.994206View

Open Access

Abstract

The optimal treatment of follicular lymphoma (FL) is not established. Rituximab's value potentially dilutes the impact of chemotherapy on FL. We reviewed 337 cases of FL treated initially with rituximab as monotherapy or with chemotherapy at the University of Iowa/Mayo Clinic from 2002 to 2009, investigating the association between chemotherapy delivery of cyclophosphamide or doxorubicin and survival. With median follow-up duration of 52.7 months, event-free survival (EFS) and overall survival (OS) were similar between the two groups, with a trend toward better EFS in the R-chemotherapy cohort (hazard ratio [HR] = 1.24, p = 0.28). In the R-chemotherapy group, increased total dose delivery and delivered dose intensity of doxorubicin were associated with improved EFS only in patients who did not receive R-maintenance (HR = 0.81; p = 0.02 and HR = 0.94; p = 0.04). Cyclophosphamide delivery was not associated with EFS. Thus, in the immunochemotherapy era, chemotherapy delivery strategy requires re-evaluation.

Follicular lymphoma

treatment delivery

dose intensity

immunochemotherapy

Details

Title: Subtitle: Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource
Creators: Kitsada Wudhikarn - Department of Medicine, College of Medicine, University of Iowa
Brian J Smith - Holden Comprehensive Cancer Center
Anna M Button - Holden Comprehensive Cancer Center
Thomas M Habermann - Division of Hematology, Mayo Clinic
Carrie A Thompson - Division of Hematology, Mayo Clinic
Lori J Rosenstein - Holden Comprehensive Cancer Center
Sergei I Syrbu - Department of Pathology, College of Medicine, University of Iowa
George J Weiner - Holden Comprehensive Cancer Center
James R Cerhan - Division of Epidemiology, Mayo Clinic
Brian K Link - Holden Comprehensive Cancer Center
Resource Type: Journal article
Publication Details: Leukemia & lymphoma, Vol.56(8), pp.2365-2372
DOI: 10.3109/10428194.2014.994206
PMID: 25530345
NLM abbreviation: Leuk Lymphoma
ISSN: 1042-8194
eISSN: 1029-2403
Publisher: Taylor & Francis
Language: English
Date published: 08/03/2015
Academic Unit: Epidemiology; Pathology; Pharmaceutical Sciences and Experimental Therapeutics; Biostatistics; Holden Comprehensive Cancer Center; Internal Medicine
Record Identifier: 9983997366402771

Metrics

19 Record Views

1 Times Cited - Web of Science

See more details